Thermo Fisher Scientific (TMO) reported strong second-quarter earnings that surpassed analyst expectations, leading the company to raise its guidance for the full fiscal year. The firm posted a 14% year-over-year increase in net income to $1.55 billion, with adjusted earnings of $5.37 per share, beating estimates of $5.12-$5.13 per share. Despite a 1% revenue decline to $10.54 billion, which still slightly exceeded projections, key segments such as Analytical Instruments saw growth. The company now expects full-year revenue of $42.4 to $43.3 billion and adjusted EPS of $21.29 to $22.07. Shares fell by 1.7% pre-market despite the positive earnings report, reflecting a cautious market response. Analysts suggest that future stock performance will heavily depend on management's commentary and the biotech funding environment.